Moderna has received emergency use listing (EUL) from the World Health Organization (WHO) for its Covid-19 vaccine to prevent the disease in individuals aged 18 years and above.
Referred to in the US as the Moderna COVID-19 Vaccine, it is an mRNA vaccine against the disease encoding for a prefusion stabilised form of the Spike (S) protein.
It was co-developed by Moderna along with the National Institute of Allergy and Infectious Diseases鈥� (NIAID) Vaccine Research Center researchers.
The EUL allows several countries across the globe to accelerate their own regulatory approval processes to procure the vaccine and inoculate people.
It aids UNICEF and the PAHO Revolving Fund to obtain the vaccine for supply to needy countries.
Furthermore, a EUL is necessary to supply Covid-19 vaccines to a global mechanism called COVAX Facility. It enables pooled vaccine procurement and supply to participating countries, including those with lower-income.
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataModerna CEO St茅phane Bancel said: 鈥淲e are actively participating in discussions with multilateral organisations, such as COVAX, to help protect populations around the world.
鈥淭his EUL is an incredible step forward as we continue our quest to ensure that people on every continent have access to our mRNA vaccine so that we can defeat the devastating Covid-19 pandemic.鈥�
The latest approval is based on the totality of scientific evidence submitted by Moderna, which includes data analysis from the Phase III clinical study reported in November last year.
In December last year, the US Food and Drug Administration (FDA) had聽authorised the Moderna COVID-19 Vaccine for emergency use聽in adult individuals.
In addition, the company has also received authorisation for the vaccine in the European Union, UK, Canada, Israel, Switzerland, Singapore, Qatar and Taiwan.
Last month, the company鈥檚聽Covid-19 variant vaccines showed an increase in neutralising titers聽against SARS-CoV-2 variants of concern according to the latest data from a preclinical study of its candidates mRNA-1273.351 and mRNA-1273.211.
